{"address1": "2-5-1, Nihonbashi-Honcho", "address2": "Chuo-Ku", "city": "Tokyo", "zip": "103-8411", "country": "Japan", "phone": "81 3 3244 3000", "website": "https://www.astellas.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company has a joint research agreement with Veneno Technologies Co. Ltd. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Naoki  Okamura BSc", "title": "Pres, CEO,CFO & Director", "fiscalYear": 2021, "totalPay": 1103196, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nobue  Yasuda", "title": "Gen. Mang. of Fin. & Accounting Department", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshitsugu  Shitaka Ph.D.", "title": "Chief Scientific Officer & Sr. Managing Exec. Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Catherine B. Levitt", "title": "Gen. Counsel", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Katsuyoshi  Sugita", "title": "Chief People Officer and Chief Ethics & Compliance Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stig  Ogata", "title": "VP of Corp. Communications", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Collette  Taylor", "age": 59, "title": "Sr. VP of HR", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tatjana  Dragovic", "title": "Sr. VP and Head of Ethics & Compliance", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nobuaki  Tanaka", "title": "Pres of Japan Commercial & Sr. Corp. Exec.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Krivoshik M.D., Ph.D.", "title": "Sr. VP & Therapeutic Area and Head for Oncology", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 2, "compensationRisk": 1, "shareHolderRightsRisk": 5, "overallRisk": 2, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 2, "previousClose": 15.345, "open": 15.345, "dayLow": 15.345, "dayHigh": 15.345, "regularMarketPreviousClose": 15.345, "regularMarketOpen": 15.345, "regularMarketDayLow": 15.345, "regularMarketDayHigh": 15.345, "dividendRate": 0.52, "dividendYield": 0.0342, "exDividendDate": 1695859200, "payoutRatio": 0.7335, "fiveYearAvgDividendYield": 2.32, "beta": 0.559381, "trailingPE": 27.9, "forwardPE": 13.228449, "volume": 2, "regularMarketVolume": 2, "averageVolume": 2138, "averageVolume10days": 1140, "averageDailyVolume10Day": 1140, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 28243699712, "fiftyTwoWeekLow": 12.77, "fiftyTwoWeekHigh": 16.71, "priceToSalesTrailing12Months": 0.018598279, "fiftyDayAverage": 14.4064, "twoHundredDayAverage": 14.45205, "trailingAnnualDividendRate": 60.0, "trailingAnnualDividendYield": 3.9100683, "currency": "USD", "enterpriseValue": -274071126016, "profitMargins": 0.065, "floatShares": 1785984670, "sharesOutstanding": 1808870016, "heldPercentInsiders": 0.0038400001, "heldPercentInstitutions": 0.51078, "impliedSharesOutstanding": 0, "bookValue": 833.291, "priceToBook": 0.018414935, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1680220800, "netIncomeToCommon": 98714001408, "trailingEps": 0.55, "forwardEps": 1.16, "pegRatio": 17993.1, "lastSplitFactor": "5:1", "lastSplitDate": 1395878400, "enterpriseToRevenue": -0.18, "enterpriseToEbitda": -0.736, "52WeekChange": 0.05065024, "SandP52WeekChange": 0.046755195, "lastDividendValue": 0.226, "lastDividendDate": 1680134400, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ALPMF", "underlyingSymbol": "ALPMF", "shortName": "ASTELLAS PHARMA", "longName": "Astellas Pharma Inc.", "firstTradeDateEpochUtc": 1272288600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f67bcc46-0813-38e0-9323-7bf0cf674275", "messageBoardId": "finmb_874641", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.345, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 376839995392, "totalCashPerShare": 208.241, "ebitda": 372395016192, "totalDebt": 74999996416, "quickRatio": 1.133, "currentRatio": 1.446, "totalRevenue": 1518618935296, "debtToEquity": 4.974, "revenuePerShare": 834.397, "returnOnAssets": 0.0696, "returnOnEquity": 0.06651, "freeCashflow": 216459755520, "operatingCashflow": 327766999040, "revenueGrowth": 0.166, "grossMargins": 0.81012, "ebitdaMargins": 0.24521999, "operatingMargins": 0.17559, "financialCurrency": "JPY", "trailingPegRatio": null}